SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Citigroup Maintains Buy on Ovid Therapeutics, Raises Price Target to $10

Citigroup maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $9 to $10.

Benzinga · 08/26/2020 11:32
Citigroup maintains Ovid Therapeutics (NASDAQ: OVID) with a Buy and raises the price target from $9 to $10.